26Aug
Financial Daily Dose 8.26.2019 | Top Story: Amgen to Pay More Than $13 Billion for Otezla
Amgen will pay $13.4 billion in cash to buy psoriasis treatment Otezla, a deal that will “pave the way for Bristol-Myers Squibb to complete its acquisition of Celgene” by addressing “regulatory concerns over their union”....
By:
Robins Kaplan LLP
Related
Plan sponsors with their proprietary funds have a unique problem. Using proprietary funds will lead ...
Read More >
The patchwork of federal, state and local laws addressing leaves of absence, protections of people w...
Read More >
Must 100% of Service Charges Be Distributed to Service Employees? A June 27, 2019 California appell...
Read More >
For M&A transactions in Germany and beyond, Foreign Investment Control screenings have become an ind...
Read More >
If you’re currently sheltering in place, hoping to read something to take your mind off the novel c...
Read More >
On Sept. 12, 2019, the New York City Council passed a law, Int. 0136-A, that expands the scope of th...
Read More >